SG194453A1 - Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset - Google Patents

Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset Download PDF

Info

Publication number
SG194453A1
SG194453A1 SG2013075668A SG2013075668A SG194453A1 SG 194453 A1 SG194453 A1 SG 194453A1 SG 2013075668 A SG2013075668 A SG 2013075668A SG 2013075668 A SG2013075668 A SG 2013075668A SG 194453 A1 SG194453 A1 SG 194453A1
Authority
SG
Singapore
Prior art keywords
treatment
cancer
motesanib
small cell
cell lung
Prior art date
Application number
SG2013075668A
Other languages
English (en)
Inventor
Yong-Jiang Hei
Bin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG194453A1 publication Critical patent/SG194453A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2013075668A 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset SG194453A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475163P 2011-04-13 2011-04-13
PCT/US2012/033376 WO2012142325A1 (en) 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset

Publications (1)

Publication Number Publication Date
SG194453A1 true SG194453A1 (en) 2013-12-30

Family

ID=46018098

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013075668A SG194453A1 (en) 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset

Country Status (7)

Country Link
JP (1) JP2014510793A (ko)
KR (1) KR20140022876A (ko)
CN (1) CN103764139A (ko)
AU (1) AU2012242773A1 (ko)
SG (1) SG194453A1 (ko)
TW (1) TW201304777A (ko)
WO (1) WO2012142325A1 (ko)

Also Published As

Publication number Publication date
CN103764139A (zh) 2014-04-30
KR20140022876A (ko) 2014-02-25
WO2012142325A1 (en) 2012-10-18
JP2014510793A (ja) 2014-05-01
TW201304777A (zh) 2013-02-01
AU2012242773A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
NZ602385A (en) Methods of treating cancer
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2015008114A (es) Derivados de exendina-4.
PH12015500431A1 (en) Glucosylceramide synthase inhibitors
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
MX2016011045A (es) Terapia de combinacion para cancer.
NZ701553A (en) Medicine comprising combination of general anesthetic drug and hydrogen
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2012082821A3 (en) Melanoma treatments
MX2015015601A (es) Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1).
BR112013019080A2 (pt) métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
SG194453A1 (en) Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset
EP2879712A4 (en) HISTOLOGICAL MARKERS FOR THE IDENTIFICATION OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA FOR ANTI-EGFR DRUG TREATMENT
MX2012003287A (es) Uso de la identificacion microambiental de sparc en el tratamiento del cancer.
SG10201908587PA (en) Treatment regimens
MX2015004940A (es) Tratamiento de depresion y ptsd.
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
UA73001U (ru) Способ лечения больных туберкулезом легких в сочетании с ВИЧ-инфекцией/СПИДом
UA78287U (ru) Способ медицинской реабилитации больных ишемической болезнью сердца на фоне метаболического синдрома
UA84191U (ru) Способ лечения больных неалкогольным стеатогепатитом на фоне сахарного диабета 2-го типа
UA67294U (uk) Спосіб прогнозування перебігу захворювання у хворих на рак шлунка